[go: up one dir, main page]

UY25204A1 - Agonistas de prostaglandinas útiles en el tratamiento de desórdenes óseos - Google Patents

Agonistas de prostaglandinas útiles en el tratamiento de desórdenes óseos

Info

Publication number
UY25204A1
UY25204A1 UY25204A UY25204A UY25204A1 UY 25204 A1 UY25204 A1 UY 25204A1 UY 25204 A UY25204 A UY 25204A UY 25204 A UY25204 A UY 25204A UY 25204 A1 UY25204 A1 UY 25204A1
Authority
UY
Uruguay
Prior art keywords
prostaglandin agonists
alkyl
pharmaceutically acceptable
phenyl
treatment
Prior art date
Application number
UY25204A
Other languages
English (en)
Inventor
Kimberly Cameron
Robert Louis Rosati
Bruce Allen Lefker
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY25204A1 publication Critical patent/UY25204A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

La invención se refiere a agonistas de prostaglandinas, procedimientos de uso de dichos agonistas de prostaglandinas, composiciones farmacéuticas que contienen dichos agonistas de prostaglandinas y estuches de ensayo que los contienen. Los agonistas de prostaglandinas son útiles para el tratamiento de los trastornos óseos, incluyendo la osteoporosis. Son compuestos de fórmula l (como es el caso del ácido (3-(((4-dimetilamino-benzil)-(piridin-3-sulfonil)-amino)-metil)-fenoxi)-acético) profármacos de los mismos y las sales farmacéuticamente aceptables de dichos compuestos y profármacos en la que A es SO7, CO; G es fenilo opcionalmente sustituido con sustituyentes seleccionados del grupo formado por: alquilo, alcoxi, halo, nitro, ciano, alcoxicarbonilo, alcanoilamino, tienilo, imidazolilo etc; B es N; Q es alquílenlo, alquil-fenixo, alquiltienilo, etc; Z es carboxi; K es un enlace, alquileno, tioalquileno, alquilen, tioalquileno u oxialquileno; cuando Q no es un enlace, K esta opcionalmente mono-, di-, o tri-sustituido independientemente con cloro, fluoro, hidroxi o metilo; M es fenilo el cual puede estar sustituido, benzoimidazolilo o benzofuranilo; etc. Una composición farmacéutica que contiene una cantidad de un compuesto de fórmula l, un pro fármaco de l mismo o una sal farmacéuticamente aceptable de dicho compuesto o dicho profármaco, y un vehículo o diluyente farmacéuticamente aceptable.
UY25204A 1997-10-10 1998-10-08 Agonistas de prostaglandinas útiles en el tratamiento de desórdenes óseos UY25204A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6172797P 1997-10-10 1997-10-10

Publications (1)

Publication Number Publication Date
UY25204A1 true UY25204A1 (es) 2000-12-29

Family

ID=22037728

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25204A UY25204A1 (es) 1997-10-10 1998-10-08 Agonistas de prostaglandinas útiles en el tratamiento de desórdenes óseos

Country Status (44)

Country Link
US (2) US6498172B1 (es)
EP (1) EP1021410B1 (es)
JP (3) JP3664651B2 (es)
KR (1) KR100369697B1 (es)
CN (2) CN1211367C (es)
AP (1) AP1156A (es)
AR (1) AR015954A1 (es)
AT (1) ATE349428T1 (es)
AU (1) AU731509B2 (es)
BG (1) BG65238B1 (es)
BR (1) BR9813028A (es)
CA (1) CA2305548C (es)
DE (1) DE69836752T2 (es)
DK (1) DK1021410T3 (es)
DZ (1) DZ2621A1 (es)
EA (1) EA003396B1 (es)
ES (1) ES2277390T3 (es)
GT (2) GT199800158A (es)
HN (1) HN1998000157A (es)
HR (1) HRP20000201B1 (es)
HU (1) HUP0100101A3 (es)
ID (1) ID24836A (es)
IL (2) IL134851A0 (es)
IS (1) IS5405A (es)
MA (1) MA26551A1 (es)
MY (1) MY129189A (es)
NO (1) NO316733B1 (es)
NZ (1) NZ503165A (es)
OA (1) OA11346A (es)
PA (1) PA8461301A1 (es)
PE (1) PE121199A1 (es)
PL (1) PL340014A1 (es)
PT (1) PT1021410E (es)
RS (1) RS50012B (es)
SA (2) SA98190804B1 (es)
SI (1) SI1021410T1 (es)
SK (1) SK286136B6 (es)
TN (1) TNSN98182A1 (es)
TR (1) TR200000927T2 (es)
TW (1) TW570913B (es)
UA (1) UA67754C2 (es)
UY (1) UY25204A1 (es)
WO (1) WO1999019300A1 (es)
ZA (1) ZA989230B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP1000619A3 (en) * 1998-06-23 2002-07-24 Pfizer Products Inc. Method for treating glaucoma
CZ20013174A3 (cs) 1999-03-05 2002-02-13 The Procter & Gamble Company C16 nenasycené FP-selektivní prostaglandinové analogy
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
IL141120A0 (en) 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
WO2003043576A2 (en) * 2001-11-20 2003-05-30 Depuy Products, Inc. Flowable osteogenic and chondrogenic compositions
RU2004116318A (ru) * 2001-11-30 2005-03-27 Пфайзер Продактс Инк. (Us) Фармацевтические композиции и споосбы введения селективных агонистов ep2-рецептора
PL370085A1 (en) * 2001-11-30 2005-05-16 Pfizer Inc. Controlled release polymeric compositions of bone growth promoting compounds
GB2400100B (en) * 2002-01-31 2006-04-12 Pfizer Prod Inc Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid
CA2482382A1 (en) * 2002-04-12 2003-10-23 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
AU2003241601A1 (en) 2002-05-24 2003-12-12 Pharmacia Corporation Anilino liver x-receptor modulators
MXPA04011690A (es) 2002-05-24 2005-03-31 Pharmacia Corp Moduladores de receptor x de higado de sulfona.
JP2006021998A (ja) * 2002-07-18 2006-01-26 Ono Pharmaceut Co Ltd Ｅｐ２アゴニストを有効成分とする月経困難症治療剤
WO2004032965A1 (ja) 2002-10-10 2004-04-22 Ono Pharmaceutical Co., Ltd. 内因性修復因子産生促進剤
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
KR20050105511A (ko) * 2003-03-04 2005-11-04 화이자 프로덕츠 인크. 의학적 치료에서 ｅｐ2 선택적 수용체 효능제의 용도
US20070270489A1 (en) 2003-07-25 2007-11-22 Ono Pharmaceutical Co., Ltd. Remedy for Cartilage-Related Diseases
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
CA2571482A1 (en) * 2004-06-21 2005-12-29 Pharmacia & Upjohn Company Llc Pyk2 inhibitors for stimulation of osteoblast function
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
US7858650B2 (en) 2004-10-22 2010-12-28 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation
US9040558B2 (en) 2004-12-31 2015-05-26 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
TWI404529B (zh) 2005-06-03 2013-08-11 Ono Pharmaceutical Co 神經再生及／或保護劑
US7915316B2 (en) 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
UA94953C2 (en) * 2006-07-28 2011-06-25 Пфайзер Продактс Инк. Ep2 agonists
BRPI0714683A2 (pt) 2006-07-28 2013-03-26 Pfizer Prod Inc agonistas ep2
WO2008058766A1 (en) 2006-11-16 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection
WO2008073748A1 (en) * 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
WO2009025793A2 (en) * 2007-08-21 2009-02-26 Senomyx, Inc. Human t2r bitterness receptors and uses thereof
MX2010002300A (es) * 2007-08-29 2010-03-18 Pfizer Prod Inc Polimorfos de sal sodica del acido (3-(((4-terc-butil-bencil)-(pir idin-3-sulfonil)-amino)-metil)-fenoxi)-acetico o un hidrato de los mismos y procedimientos para fabricar los mismos.
US20110046385A1 (en) * 2007-08-29 2011-02-24 Pfizer Products Inc. Polymorphs Of Prostaglandin Agonists And Methods For Making The Same
WO2009027803A2 (en) * 2007-08-29 2009-03-05 Pfizer Products Inc. Polymorphs of (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)- phenoxy)-acetic acid, free acid
WO2009113600A1 (ja) * 2008-03-12 2009-09-17 宇部興産株式会社 ピリジルアミノ酢酸化合物
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
CA2757291C (en) 2009-03-30 2017-05-23 Ube Industries, Ltd. Medical composition for treatment or prophylaxis of glaucoma
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
WO2011078303A1 (ja) 2009-12-25 2011-06-30 宇部興産株式会社 アミノピリジン化合物
EP3056198A2 (en) 2010-09-16 2016-08-17 MSP Co., Ltd Use of compounds for inducing differentiation of mesenchymal stem cells to chondrocytes
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
IN2014CN02290A (es) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr
US8772541B2 (en) * 2011-12-15 2014-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
JP6400479B2 (ja) 2012-10-29 2018-10-03 株式会社カルディオ 肺疾患特異的治療剤
US9487485B2 (en) 2013-02-28 2016-11-08 Takeda Pharmaceutical Company Limited Method for producing sulfonyl chloride compound
US9676720B2 (en) 2013-03-28 2017-06-13 Ube Industries, Ltd. Substituted biaryl compound
JP6449166B2 (ja) 2013-10-15 2019-01-09 小野薬品工業株式会社 薬剤溶出性ステントグラフト
JP2017206444A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 置換フェニル化合物
CN114591227A (zh) * 2021-12-28 2022-06-07 上海冬洋生物科技有限公司 一种ep2受体选择性的前列腺素e2激动剂的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR897566A (fr) 1942-08-28 1945-03-26 Bopp & Reuther Gmbh Machine à rotors
US3442890A (en) 1965-06-15 1969-05-06 Mead Johnson & Co Substituted 3-benzazocin-16-ones
US3528961A (en) 1966-08-16 1970-09-15 Allied Chem Monoazo dyes from e-caprolactam
US3780095A (en) 1970-04-08 1973-12-18 Byk Gulden Lomberg Chem Fab Acylated anilino-carboxylic acids and their salts
US3987091A (en) 1973-04-12 1976-10-19 Merck & Co., Inc. 11,12-secoprostaglandins
US4033996A (en) 1973-04-25 1977-07-05 Merck & Co., Inc. 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
JPS5019756A (es) 1973-06-25 1975-03-01
SE7414770L (es) 1973-12-13 1975-06-16 Merck & Co Inc
DK366475A (da) 1974-08-30 1976-03-01 Merck & Co Inc Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner
US3991106A (en) 1974-09-13 1976-11-09 Merck & Co., Inc. 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4055596A (en) * 1974-09-13 1977-10-25 Merck & Co., Inc. 11,12-Seco-prostaglandins
US4175203A (en) 1976-12-17 1979-11-20 Merck & Co., Inc. Interphenylene 11,12-secoprostaglandins
US4112236A (en) 1977-04-04 1978-09-05 Merck & Co., Inc. Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins
US4097601A (en) * 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4243678A (en) 1977-12-30 1981-01-06 Byk Gulden Lomberg Chemische Fabrik Gmbh Acylhydrocarbylaminoalkanoic acids, compositions and uses
DE3000377A1 (de) 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3042482A1 (de) 1980-11-11 1982-06-24 A. Nattermann & Cie GmbH, 5000 Köln N-benzoyl- (omega) -anilinoalkancarbonsaeuren, -salze und -ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
EP0068968B1 (fr) 1981-06-16 1985-09-18 Choay S.A. Nouveaux médicaments contenant à titre de substance active des composés du type arylbenzènesulfonamide et leurs procédés de préparation
DK373383A (da) 1982-08-20 1984-02-21 Midit Fremgangsmaade til fremstilling af omega-aminosyrederivater
DE3719046A1 (de) 1987-06-06 1988-12-15 Basf Ag Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
US5081152A (en) 1989-07-05 1992-01-14 Kotobuki Seiyaku Co., Ltd. Azulene derivatives as thromboxane a2 and prostaglandin endoperoxide receptor antagonist
JPH0467105A (ja) * 1990-07-09 1992-03-03 Nippon Telegr & Teleph Corp <Ntt> 偏波保持光ファイバ
GB9110722D0 (en) * 1991-05-17 1991-07-10 Fujisawa Pharmaceutical Co Amine derivatives
GB9116732D0 (en) * 1991-08-02 1991-09-18 Fujisawa Pharmaceutical Co Indole derivatives
CA2113787A1 (en) * 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
DE19648793A1 (de) 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
AUPO440696A0 (en) * 1996-12-30 1997-01-23 Fujisawa Pharmaceutical Co., Ltd. New use
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
RU2004116318A (ru) * 2001-11-30 2005-03-27 Пфайзер Продактс Инк. (Us) Фармацевтические композиции и споосбы введения селективных агонистов ep2-рецептора
GB2400100B (en) * 2002-01-31 2006-04-12 Pfizer Prod Inc Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid

Also Published As

Publication number Publication date
BG65238B1 (bg) 2007-09-28
GT199800158A (es) 2000-04-01
DK1021410T3 (da) 2007-04-02
AU731509B2 (en) 2001-03-29
DZ2621A1 (fr) 2003-03-08
NZ503165A (en) 2001-07-27
JP2004155759A (ja) 2004-06-03
EA003396B1 (ru) 2003-04-24
JP4031736B2 (ja) 2008-01-09
UA67754C2 (uk) 2004-07-15
SA98190804A (ar) 2005-12-03
AP1156A (en) 2003-06-30
SK4752000A3 (en) 2001-05-10
NO20001754L (no) 2000-06-07
JP2007246532A (ja) 2007-09-27
SA06260449B1 (ar) 2007-08-07
WO1999019300A1 (en) 1999-04-22
SK286136B6 (sk) 2008-04-07
SA98190804B1 (ar) 2006-07-30
HN1998000157A (es) 1999-06-02
KR100369697B1 (ko) 2003-02-05
JP4796006B2 (ja) 2011-10-19
US7442702B2 (en) 2008-10-28
IS5405A (is) 2000-03-14
IL134851A (en) 2007-06-17
ID24836A (id) 2000-08-24
NO316733B1 (no) 2004-04-14
HK1031884A1 (en) 2001-06-29
US20030078261A1 (en) 2003-04-24
EP1021410A1 (en) 2000-07-26
TR200000927T2 (tr) 2000-11-21
BG104315A (en) 2000-12-29
HRP20000201A2 (en) 2000-06-30
TNSN98182A1 (fr) 2005-03-15
CN1566096A (zh) 2005-01-19
AR015954A1 (es) 2001-05-30
NO20001754D0 (no) 2000-04-05
PT1021410E (pt) 2007-02-28
CN1275123A (zh) 2000-11-29
CN1211367C (zh) 2005-07-20
GT199800158AA (es) 2000-04-01
KR20010031035A (ko) 2001-04-16
HRP20000201B1 (en) 2003-06-30
ZA989230B (en) 2000-04-10
SI1021410T1 (sl) 2007-06-30
RS50012B (sr) 2008-09-29
EP1021410B1 (en) 2006-12-27
JP2001519414A (ja) 2001-10-23
PL340014A1 (en) 2001-01-15
ES2277390T3 (es) 2007-07-01
HUP0100101A3 (en) 2001-12-28
AU9181598A (en) 1999-05-03
OA11346A (en) 2003-12-11
EA200000298A1 (ru) 2000-10-30
CA2305548A1 (en) 1999-04-22
ATE349428T1 (de) 2007-01-15
JP3664651B2 (ja) 2005-06-29
TW570913B (en) 2004-01-11
HUP0100101A2 (hu) 2001-06-28
MY129189A (en) 2007-03-30
DE69836752T2 (de) 2007-10-11
US6498172B1 (en) 2002-12-24
MA26551A1 (fr) 2004-12-20
BR9813028A (pt) 2000-08-15
CA2305548C (en) 2008-12-02
PA8461301A1 (es) 2000-05-24
PE121199A1 (es) 1999-12-02
YU18400A (sh) 2003-08-29
DE69836752D1 (de) 2007-02-08
AP9801356A0 (en) 1998-12-31
IL134851A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
UY25204A1 (es) Agonistas de prostaglandinas útiles en el tratamiento de desórdenes óseos
ES2139943T3 (es) Nuevos inhibidores de la sintasa de prostaglandina.
PE20020476A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
PE44599A1 (es) Inhibidores de la enzima acido nitrico sintasa
EA200500312A1 (ru) Новые спироконденсированные хиназолиноны и их применение в качестве ингибиторов фосфодиэстераз
BR0309534A (pt) Composto, composição farmacêutica, e, uso de um composto
EA200200770A1 (ru) Производные пурина
AR051735A1 (es) Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos.
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
DK1436257T3 (da) Oxim-analogica af 1-alpha, 25-dihydroxy-vitamin-D3 med ringe kalcemisk virkning
SV2010003523A (es) Metodo para producir 2&#39; -desoxi - 5- azacitidina ( decitabina ) ref. prd2888-pct-slv-/fv/im
WO2000067735A3 (en) USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION
AR018186A1 (es) Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto
PE20080835A1 (es) Derivados novedosos de aminopiridina que tienen accion inhibidora selectiva sobre aurora a
AR064307A1 (es) Monofosfatos utiles para el tratamiento de la inflamacion pulmonar y broncoconstriccion, formulaciones aerosolicas que los contienen, y metodo de preparacion.
DE69918465D1 (de) Sulfonamidhydroxamate
EA200000804A1 (ru) Мета-азациклические соединения аминобензойной кислоты и их производные, являющиеся ингибиторами интегрина
EA200200774A1 (ru) Новые соединения, обладающие гиполипидемической, гипохолестеринемической активностью, способ их получения и содержащие их композиции
PA8426801A1 (es) Composiciones farmaceuticas para el tratamiento de la rinitis.
AR049883A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos
PT1078928E (pt) Derivados da piridina processo para a sua preparacao e as composicoes farmaceuticas que os contem
ECSP066317A (es) Compuestos
EA200400848A1 (ru) Производные триазолохинолина, применимые в качестве лигандов аденозиновых рецепторов
AR059546A1 (es) Derivados de cromen -2-ona utiles como inhibidores de recaptacion del neurotransmisor de monoamina
MX9307271A (es) Derivados de 2-alcoxi-2 imidazolin-5-onas, procedimiento para su preparacion y composicion fungicida que los contiene.

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20100625

VENC Patent expired

Effective date: 20181008